Silverfin false 31/03/2023 01/04/2022 31/03/2023 Dr M K Molyneux 19/10/2017 Dr N J Rasburn 19/10/2017 22 October 2023 The principal activity of the Company during the financial year was investment holdings. 11022693 2023-03-31 11022693 bus:Director1 2023-03-31 11022693 bus:Director2 2023-03-31 11022693 2022-03-31 11022693 core:CurrentFinancialInstruments 2023-03-31 11022693 core:CurrentFinancialInstruments 2022-03-31 11022693 core:ShareCapital 2023-03-31 11022693 core:ShareCapital 2022-03-31 11022693 core:RetainedEarningsAccumulatedLosses 2023-03-31 11022693 core:RetainedEarningsAccumulatedLosses 2022-03-31 11022693 core:CostValuation 2022-03-31 11022693 core:CostValuation 2023-03-31 11022693 core:SubsidiariesWithMaterialNon-controllingInterests core:CurrentFinancialInstruments 2023-03-31 11022693 core:SubsidiariesWithMaterialNon-controllingInterests core:CurrentFinancialInstruments 2022-03-31 11022693 2022-04-01 2023-03-31 11022693 bus:FullAccounts 2022-04-01 2023-03-31 11022693 bus:SmallEntities 2022-04-01 2023-03-31 11022693 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 11022693 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 11022693 bus:Director1 2022-04-01 2023-03-31 11022693 bus:Director2 2022-04-01 2023-03-31 11022693 2021-04-01 2022-03-31 11022693 core:Subsidiary1 2022-04-01 2023-03-31 11022693 core:Subsidiary1 1 2022-04-01 2023-03-31 11022693 core:Subsidiary1 1 2021-04-01 2022-03-31 11022693 core:Subsidiary2 2022-04-01 2023-03-31 11022693 core:Subsidiary2 1 2022-04-01 2023-03-31 11022693 core:Subsidiary2 1 2021-04-01 2022-03-31 iso4217:GBP xbrli:pure decimalUnit

Company No: 11022693 (England and Wales)

GLANSO HOLDINGS LIMITED

Unaudited Financial Statements
For the financial year ended 31 March 2023
Pages for filing with the registrar

GLANSO HOLDINGS LIMITED

Unaudited Financial Statements

For the financial year ended 31 March 2023

Contents

GLANSO HOLDINGS LIMITED

COMPANY INFORMATION

For the financial year ended 31 March 2023
GLANSO HOLDINGS LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 31 March 2023
DIRECTORS Dr M K Molyneux
Dr N J Rasburn
REGISTERED OFFICE Atherton House
Hollybush Lane
Bristol
BS9 1JB
England
United Kingdom
COMPANY NUMBER 11022693 (England and Wales)
CHARTERED ACCOUNTANTS Albert Goodman LLP
3 Filers Way
Weston Gateway Business Park
Weston-super-Mare
Somerset
BS24 7JP
GLANSO HOLDINGS LIMITED

BALANCE SHEET

As at 31 March 2023
GLANSO HOLDINGS LIMITED

BALANCE SHEET (continued)

As at 31 March 2023
Note 2023 2022
£ £
Fixed assets
Investments 3 10,170 10,170
10,170 10,170
Current assets
Debtors 4 109,764 189,475
Cash at bank and in hand 535 535
110,299 190,010
Creditors: amounts falling due within one year 5 ( 2,938) ( 85,830)
Net current assets 107,361 104,180
Total assets less current liabilities 117,531 114,350
Net assets 117,531 114,350
Capital and reserves
Called-up share capital 100 100
Profit and loss account 117,431 114,250
Total shareholders' funds 117,531 114,350

For the financial year ending 31 March 2023 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Glanso Holdings Limited (registered number: 11022693) were approved and authorised for issue by the Board of Directors on 22 October 2023. They were signed on its behalf by:

Dr M K Molyneux
Director
Dr N J Rasburn
Director
GLANSO HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2023
GLANSO HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2023
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Glanso Holdings Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Atherton House, Hollybush Lane, Bristol, BS9 1JB, England, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Group accounts exemption

Group accounts exemption s399
The Company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the Company as an individual entity and not about its group.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value through profit or loss if the shares are publicly traded or their fair value can otherwise be measured reliably. Other investments are measured at cost less impairment.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

2023 2022
Number Number
Monthly average number of persons employed by the Company during the year, including directors 2 2

3. Fixed asset investments

Investments in subsidiaries

2023
£
Cost
At 01 April 2022 10,170
At 31 March 2023 10,170
Carrying value at 31 March 2023 10,170
Carrying value at 31 March 2022 10,170

Investments in shares

Name of entity Registered office Nature of business Class of
shares
Ownership
31.03.2023
Ownership
31.03.2022
Global Anaesthetic Solutions Limited PO Box 416, Atherton House, Hollybush Lane, Bristol, BS9 1JB Medical practice activities Ordinary 100.00% 100.00%
Glanso UK Limited PO Box 416, Atherton House, Hollybush Lane, Bristol, BS9 1JB Medical practice activities Ordinary 75.00% 75.00%

4. Debtors

2023 2022
£ £
Amounts owed by own subsidiaries 109,764 189,475

5. Creditors: amounts falling due within one year

2023 2022
£ £
Amounts owed to own subsidiaries 0 84,100
Other creditors 2,938 1,730
2,938 85,830